Recent News
Asbestos Awareness Week: April 1 – April 7, 2019
Asbestos Awareness Week starts today. The Asbestos Disease Awareness Organization (ADAO) is kicking off this global campaign of education and awareness about the risks of asbestos and the need for…
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
MESOTIP is a randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma In this study, patients in the experimental arm will be treated by 4 PIPAC (Cisplatine+Doxorubicine) alternating with 6 cycles of standard intravenous chemotherapy (Cisplatine+Pemetrexed).
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
For cancers, such as mesothelioma, that spread to the lining of the stomach, detecting the cancer is very difficult with CT or MRI scans. Researchers at the University of Chicago want to find out if the new experimental MRI and ultrasound imaging techniques do a better job of detecting these cancers. Researchers will use new MRI and ultrasound techniques to see if it can find evidence of cancer that has spread to the lining of the abdomen, and right now these new techniques are only used for research.
Less Invasive Surgery Produces Longer Median Survival in Mesothelioma Patients
Surgical techniques for those suffering from mesothelioma depend on how far the cancer has spread and if the patient is healthy enough to withstand such an invasive procedure. In many…
Why Does Asbestos-Related Disease Continue to Rise?
In early 2017, the Centers for Disease Control and Prevention (CDC) reported that despite the decline of asbestos use once the product became regulated in the United States, mesothelioma rates…
Targeted Immunotherapy Warrants More Research for Those Suffering from Pleural Mesothelioma
Late last month, the Clinical Respiratory Journal released their findings on the efficacy of intrapleural immunotherapy, which is a highly targeted approach of receiving immunotherapy treatment for those suffering from…
Understanding the Signs and Symptoms of Asbestos Disease
Asbestos was once considered something of a wonder material for its durability and its resistance to heat and corrosion. There was a time when it could be found in textiles,…
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results in activation of T cell proliferation and cytokine production. This is a multi-center, open-label, Phase 1 trial of orally administered CA-170 in adult patients with advanced solid tumors or lymphomas who have progressed or are non-responsive to available therapies and for which no standard therapy exists.
New Clinical Trial Underway for Immunotherapy Treatment; CA-170
A new immunotherapy treatment that has recently been administered to a patient suffering from mesothelioma has researchers and scientists optimistic that if results are positive, this treatment could be more…
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
This single-site, feasibility study to assess the initial safety and efficacy of the LUM Imaging System for in vivo imaging of metastases to the peritoneum from primary gastrointestinal cancer, ovarian cancer and mesothelioma. This feasibility study consists of two parts: (a) a dose escalation phase to select the optimal dose followed by (b) enrollment of additional patients to develop the tumor detection algorithm.
